Aptose Biosciences Inc. (APS.TO)
| Previous Close | 1.0800 |
| Open | 1.1000 |
| Bid | 1.0800 x N/A |
| Ask | 1.1100 x N/A |
| Day's Range | 1.0700 - 1.1100 |
| 52 Week Range | 1.0000 - 4.3000 |
| Volume | |
| Avg. Volume | 26,744 |
| Market Cap | 96.065M |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7990 |
| Earnings Date | Mar 21, 2022 - Mar 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.34 |
- GlobeNewswire
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS), please note that in the section of updated clinical findings with HM43239, the fifth bullet point should read "Eight total responses, including seven CRs and one PR, and favorable
- GlobeNewswire
Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today released highlights from a key opinion leader (KOL) and corporate update
- GlobeNewswire
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company’s annual and special meeting of shareholders held today, May 31, 2022 (the “Meeting”). A total of 53.46% of the common shares of the Company entitled to be voted were represented
